Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: A nemesis of platelet glycoprotein IIb/iIIa inhibitors

• Published in: Catheterization and cardiovascular interventions Vol. 49; no. 2; pp. 181 - 184
• Main Authors: Ali, Arshad, Patil, Sandish, Grady, Kevin J., Schreiber, Theodore L.
• Format: Journal Article
• Language: English
• Published: New York John Wiley & Sons, Inc 01.02.2000; Wiley-Liss
• Subjects: abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal - adverse effects; Biological and medical sciences; Drug toxicity and drugs side effects treatment; Fatal Outcome; Female; Hemoptysis - chemically induced; Humans; Immunoglobulin Fab Fragments - adverse effects; Male; Medical sciences; Myocardial Ischemia - therapy; Pharmacology. Drug treatments; Platelet Aggregation Inhibitors - adverse effects; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors; Pulmonary Alveoli; pulmonary hemorrhage; Thrombosis - prevention & control; tirofiban; Toxicity: blood; Tyrosine - adverse effects; Tyrosine - analogs & derivatives; Human; Abciximab; Respiratory disease; Toxicity; Lung; Coronary artery; Instrumentation therapy; Instrumental dilatation; Hemorrhage; Antiplatelet agent; Case study; Chemotherapy; Treatment; Tirofiban
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/(SICI)1522-726X(200002)49:2<181::AID-CCD14>3.0.CO;2-J

We describe three patients who developed severe pulmonary hemorrhage following administration of tirofiban (one patient) and abciximab (two patients). Pulmonary hemorrhage associated with abciximab use has been described, but to the best of our knowledge there has been no previous reports of this complication with tirofiban. Cathet. Cardiovasc. Intervent. 49:181–184, 2000. © 2000 Wiley‐Liss, Inc.